---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-213239"
form_type: "8-K"
ticker: "ARTV"
cik: "0001817241"
company_name: "Artiva Biotherapeutics, Inc."
filed_at: "2026-05-08T23:59:59+00:00"
generated_at: "2026-05-14T21:09:40.638894+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Artiva reports 71% ACR50 in refractory RA at 6 months, FDA alignment for Phase 3 trial; Q1 net loss $23.5M

## Summary
- 71% ACR50 response in company-sponsored Phase 2a at 6 months (5/7 patients); no relapses or new immunomodulatory agents.
- FDA aligned on single Phase 3 registrational trial for AlloNK in ~150 refractory RA patients; ACR50 at 6 months primary endpoint.
- Safety: no CRS, ICANS, or AlloNK-related discontinuations; outpatient administration in community rheumatology clinics.
- Q1 net loss $23.5M; cash $86.8M expected to fund operations into Q2 2027.
- ATM sales suspended under Sales Agreement with Leerink; agreement remains in effect.

## SEC filing metadata
- accession: 0001193125-26-213239
- form_type: 8-K
- ticker: ARTV
- cik: 0001817241
- company_name: Artiva Biotherapeutics, Inc.
- filed_at: 2026-05-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1817241/000119312526213239/0001193125-26-213239-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1817241/000119312526213239/d38160d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-213239
- JSON: https://secwatch.observer/filing/0001193125-26-213239.json
- Plain text: https://secwatch.observer/filing/0001193125-26-213239.txt

## Key facts
- Earnings Releases
  Artiva Biotherapeutics, Inc. reported financial results for first quarter ended March 31, 2026.
  - Period: first quarter ended March 31, 2026
  - Result: reported results
  source text: Artiva Biotherapeutics, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1817241/000119312526213239/0001193125-26-213239-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.